A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Clinical trial NCT06148506 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06148506
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-12-28
- Primary completion
- 2027-06-30
- Enrollment
- 376
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.